



BERYL DRUGS LIMITED

Regd. Off.: 29, Neer Nagar, "Mayank Water Park Road", Bicholi Hapsi, **INDORE-452016 (M.P.) INDIA**
Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

Date: 06th July, 2026

To,
The DCS- Listing,
The Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Script Code: 524606

Sub.: Filing of Reports for the quarter ended on 30.06.2026


Dear Sir,

With reference to various conditions stipulated under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other regulation required to be complied by the listed Companies, we are enclosing herewith the following documents for your record, relating to quarter/year ended on 30th June, 2026

1. Regulation 74 (5) – Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026
2. Regulation 57(5)- Non- Applicability Certificate Under Regulation 57(5) for the quarter ended 30th June, 2026

For Beryl Drugs Limited

Sanjay Sethi
Managing Director
DIN: 00090277





BERYL DRUGS LIMITED

Regd. Off.: 29, Neer Nagar, "Mayank Water Park Road", Bicholi Hapsi, **INDORE-452016 (M.P.) INDIA**
Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

Date: 06th July, 2026

To,
The Compliance Department,
BSE Ltd,
Phiroze Jeejeebhoy Tower,
25th Floor, Dalal Street,
Mumbai - 400001

BSE CODE: 524606

Sub: Compliance under regulation 57(5) for the quarter ended 30.06.2026.

Dear Sir/Madam,

We wish to inform that Regulation 57(5) is not applicable to our company since there is no non - convertible securities for which interest/dividend/principal is payable during the quarter ended 30.06.2026.

You are requested to please take the same on record.

For Beryl Drugs Limited


Sanjay Sethi
Managing Director
DIN: 00090277

